Last reviewed: June 12, 2026

Last updated: June 12, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The supply of compounded semaglutide has shifted dramatically since 2023, when Novo Nordisk restricted wholesale access to the brand-name Ozempic and Wegovy. Despite these constraints, compounded semaglutide continues to be produced by licensed 503A compounding pharmacies across all 50 states, offering patients an accessible path to GLP-1 treatment without insurance requirements or membership fees.

Current Status of Compounded Semaglutide in 2025

Compounded semaglutide injections remain legal and available through licensed 503A compounding pharmacies, which operate under federal and state pharmacy boards rather than manufacturer approval. The FDA has not prohibited compounding of semaglutide, though it has increased oversight of quality standards and supply chain transparency. PlexusDx sources semaglutide from licensed 503A facilities that maintain strict pharmaceutical-grade manufacturing practices, ensuring consistency and sterility across all batches.

The distinction between 503A and 503B compounding matters significantly for patient safety. 503A pharmacies operate locally and compound medications for individual patients based on prescriptions, while 503B facilities prepare bulk compounds without patient-specific orders. PlexusDx exclusively partners with 503A compounding pharmacies, which means each dose is prepared according to your personalized prescription rather than manufactured in mass batches. This approach supports regulatory compliance while maintaining access to compounded semaglutide at $149 per month for the injection form.

Why Manufacturers Restricted Wholesale Access

Novo Nordisk and Eli Lilly implemented strict wholesale supply controls beginning in 2023, citing concerns about diversion of medications to black markets and counterfeit products flooding unregulated channels. The manufacturers argued that limiting supply to authorized wholesalers and pharmacy chains would prevent misuse, though this decision simultaneously reduced the raw materials available to legitimate 503A compounding pharmacies. Rather than stopping compounding entirely, this restriction shifted the sourcing model—compounders now purchase active pharmaceutical ingredients (APIs) from licensed suppliers instead of repackaging brand-name products.

The shift from brand-name diversion to API-based compounding has created a more sustainable model for patient access. Licensed 503A pharmacies source pharmaceutical-grade semaglutide APIs from FDA-registered suppliers, meaning the active ingredient meets the same purity and potency standards as branded medications. This transition ensures that compounded semaglutide remains available long-term, independent of manufacturer supply decisions. PlexusDx patients benefit from this stability, with pricing that remains flat at $149 monthly regardless of dose adjustments.

Regulatory Environment and Future Availability

The FDA has issued guidance supporting the continued practice of 503A compounding for GLP-1 medications when there is evidence of shortages or clinical need, though it has simultaneously tightened quality control requirements. State pharmacy boards continue to license and inspect 503A compounders, creating multiple layers of regulatory oversight. PlexusDx works exclusively with pharmacies that exceed baseline compliance standards, maintaining documentation of API sourcing, sterility testing, and pharmaceutical-grade manufacturing protocols.

Proposed legislation and regulatory actions over the next 2-3 years may further tighten compounding standards, but evidence suggests that 503A compounding of semaglutide will remain a legal and viable option for patients. The FDA's focus has centered on preventing 503B (bulk) compounding and illicit manufacturers rather than restricting legitimate 503A operations. For patients seeking compounded semaglutide, choosing a provider like PlexusDx that partners with verified, licensed 503A pharmacies protects against regulatory risk and ensures medication safety.

How PlexusDx Ensures Long-Term Access to Compounded GLP-1

PlexusDx maintains relationships with multiple licensed 503A compounding pharmacies across the United States, diversifying sources and ensuring uninterrupted supply even if individual pharmacies face operational changes. This network approach reduces reliance on any single supplier and allows rapid pivoting if regulatory conditions shift in specific states. PlexusDx also invests in the Precision Peptide Genetic Test, which maps 14 metabolic pathways and identifies genetic variants in GLP1R, GIPR, FTO, and MC4R genes—enabling personalized therapy selection when treatment options evolve.

Patient access remains the priority at PlexusDx, reflected in pricing transparency and no-barrier enrollment across all 50 states. Compounded semaglutide injections start at $149 per month, with HSA and FSA eligibility, and no membership or insurance requirement. As regulatory landscapes shift, PlexusDx continues to maintain compliance and offer alternative compounded GLP-1 options—including tirzepatide injections starting at $249 monthly, oral formulations, and the GLP-Squared dual-compound protocol—ensuring that patients always have personalized, accessible choices for weight loss therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide legal and safe to use?

Yes, semaglutide compounded by licensed 503A pharmacies is legal and safe when sourced from FDA-registered suppliers of pharmaceutical-grade APIs. PlexusDx exclusively partners with 503A facilities that maintain strict quality control and sterility standards. Each prescription is prepared individually according to your doctor's order, not mass-produced like 503B bulk compounds.

Will compounded semaglutide be banned or become unavailable?

Current regulatory trends do not support a ban on 503A compounding of semaglutide. The FDA has continued to support compounding during periods of shortage or clinical need, and state pharmacy boards actively license and inspect 503A operations. PlexusDx's multi-pharmacy network ensures supply continuity regardless of individual facility changes.

How does PlexusDx pricing remain stable if compounding regulations change?

PlexusDx charges a flat monthly rate for compounded semaglutide ($149 for injections) regardless of dose level, meaning your price won't increase as your dose adjusts. This pricing model is sustainable because it reflects the true cost of 503A compounding and API sourcing, not reliance on manufacturer discounts. HSA and FSA eligibility further reduce out-of-pocket costs.

What's the difference between 503A and 503B compounding, and why does it matter?

503A pharmacies compound medications for individual patients based on specific prescriptions, while 503B facilities prepare bulk batches without patient-specific orders. PlexusDx uses only 503A compounding because it ensures prescription-level customization, stronger regulatory oversight, and better traceability. 503A compounds are safer for patients seeking personalized weight loss therapy.

How does the Precision Peptide Genetic Test help if semaglutide availability changes?

The Precision Peptide Genetic Test maps genetic variants in GLP1R, GIPR, FTO, and MC4R—revealing your metabolic predispositions and response patterns to different GLP-1 medications. If compounded semaglutide access changes, your genetic insights guide selection of alternative therapies like tirzepatide or the GLP-Squared dual compound, ensuring continuity of personalized treatment.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves